Chattem Announces Noncompliance with NASDAQ Listing Rule
February 23 2010 - 4:30PM
Business Wire
As previously reported on Chattem, Inc.'s (NASDAQ: CHTT) (the
“Company”) Form 8-K filed on February 12, 2010 (the “Form 8-K”),
the Company is no longer in compliance with NASDAQ Listing Rule
5605(c) (“Rule 5605(c)”) which requires that the audit committee of
the Company's Board of Directors (the “Board”) be composed of at
least three independent directors. As more fully described in the
Form 8-K, as a result of certain appointments to, and resignations
from, the Board as contemplated by the Agreement and Plan of Merger
(the “Merger Agreement”), dated as of December 20, 2009, among the
Company, sanofi-aventis, a French société anonyme, and River
Acquisition Corp., a Tennessee corporation and an indirect
wholly-owned subsidiary of Parent, the Company has only two
independent directors, both of whom are members of the audit
committee.
On February 19, 2010, the Company received a notice from the
staff of the NASDAQ Stock Market, indicating the Company is not in
compliance with Rule 5605(c). However, consistent with Listing Rule
5605(c)(4)(A), NASDAQ will provide the Company a cure period in
order to regain compliance as follows:
- until the earlier of the
Company's next annual shareholders' meeting or February 9, 2011;
or
- if the next annual shareholder's
meeting is held before August 9, 2010 then the Company must
evidence compliance no later than August 9, 2010.
The Company must submit to NASDAQ documentation, including
biographies of any new directors, evidencing compliance with the
rules no later than this date. In the event the Company does not
regain compliance by this date, NASDAQ rules require the NASDAQ
staff to provide written notification to the Company that its
securities will be delisted.
If the merger that is contemplated by the Merger Agreement does
not occur prior to the expiration of the cure period, the Company
will take the necessary steps to appoint an additional independent
director to the Board and to the Company's audit committee in order
to comply with Rule 5605(c).
Statement on Cautionary Factors
This release contains forward-looking statements within the
meaning of the federal securities laws. Statements that are not
historical facts, including statements about our beliefs and
expectations, are forward-looking statements. Forward-looking
statements include statements preceded by, followed by or that
include the words, “believes,” “expects,” “anticipates,” “plans,”
“estimates” or similar expressions. Examples of forward-looking
statements in this release include references to our announced
transaction with sanofi-aventis. Forward-looking statements are
only predictions and are not guarantees of performance. These
statements are based on beliefs and assumptions of management,
which in turn are based on currently available information. The
forward-looking statements also involve risks and uncertainties,
which could cause actual results to differ materially from those
contained in any forward-looking statement. Many of these factors
are beyond our ability to control or predict. Important factors
that could cause actual results to differ materially from those
contained in any forward-looking statement include, but are not
limited to, the risk factors disclosed in our Annual Report on Form
10-K for the year ended November 30, 2009, as added or revised by
our subsequent Quarterly Reports on Form 10-Q, under the caption
“Risk Factors” and unexpected delays or impediments to the
announced transaction with sanofi-aventis. We believe these
forward-looking statements are reasonable; however, undue reliance
should not be placed on any forward-looking statements, which are
based on current expectations. Further, forward-looking statements
speak only as of the date they are made, and we undertake no
obligation to update publicly any of these in light of new
information or future events.
Chattem, Inc. (MM) (NASDAQ:CHTT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Chattem, Inc. (MM) (NASDAQ:CHTT)
Historical Stock Chart
From Nov 2023 to Nov 2024